Here we present a case study using an inhaled formulation of bevacizumab, a mAb VEGF-inhibitor formulated via spray drying. It was tested in a pre-clinical rat model of NSCLC and found to reduce tumor burden as effectively as injections.
Content Type: Webinar (on-demand)
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center